Molly Burich Discusses the FDA's Interchangeability Guidance Update
Molly Burich, MS, head of public policy at Boehringer Ingelheim (BI), discusses how the FDA's new guidance on interchangeability designation will improve confidence and acceptance for biosimilars during the World Biosimilar Congress USA 2020 at the Festival of Biologics USA in San Diego, California.
Molly Burich, MS, is the head of public policy at Boehringer Ingelheim.
Transcript:
What are your thoughts on the FDA's updated guidance on interchangeability?
I think the FDA has long been a proponent of not just the biosimilar pathway, but obviously getting interchangeables approved as well. From a guidance perspective, [Boehinger Ingelheim] has felt strongly that the FDA has gotten the guidance right, both in proposed and final form. We believe there does need to be an appropriately high bar, but at the same time, some product-by-product flexibility. We want to make sure that the interchangeability designation is in fact meaningful; that it’s generating a complement of data around patient switching that will help drive physician confidence and patient acceptance as well.
IGBA 2023: Dr Monique Mansoura Highlights the Intersection of Geopolitical Issues, Biopharma
February 19th 2023COVID-19 allowed governments to critically examine the biopharma space to increase access to vaccines, but there's still a way to go, according to Monique Mansoura, PhD, MBA, executive director of global health security and biotechnology at the MITRE Corporation, at the International Generic and Biosimilar Medicines Association’s annual meeting.
Dr Fran Gregory Sizes Up the US Adalimumab Market: Will Biosimilars See Success?
September 17th 2023On this episode of Not So Different, Fran Gregory, PharmD, MBA, vice president of emerging therapies at Cardinal Health, analyzes the adalimumab market so far in the United States and provides insight into how the market needs to adapt to accept these products and ensure lower drug costs for patients.
Dr Joseph Alvarnas Highlights the Current State of the Oncology Biosimilar Market
November 9th 2022Joseph Alvarnas, MD, vice president of government affairs at City of Hope and chief clinical adviser of AccessHope, explains what the recent FDA approvals of Stimufend and Vegzelma, 2 oncology biosimilars, says about the current state of the oncology biosimilar space.
Expert Opinion: What Factors Will Have the Greatest Impact on US Adoption of Humira Biosimilars?
April 12th 2022Jeffrey Casberg, vice president of pharmacy at IPD Analytics, weighs in on the factors he thinks will most affect market share among adalimumab biosimilars when they enter the US market in 2023.
